Patents by Inventor Gary lee Warren
Gary lee Warren has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11957731Abstract: The present invention relates to reconstituted high density lipoprotein (rHDL) formulations comprising an apolipoprotein, a lipid and a lyophilization stabilizer. Said formulations have reduced renal toxicity and good long-term stability, especially in lyophilized form.Type: GrantFiled: September 2, 2022Date of Patent: April 16, 2024Assignee: CSL LimitedInventors: Yvonne Vucica, Gary Lee Warren
-
Patent number: 11732028Abstract: A method for purifying Apo A-I is provided including the steps of providing a solution comprising Apo A-I and guanidine hydrochloride and filtering the solution through a filter having a pore size in a range from 15 nm to 35 nm to thereby reduce viral contamination of the Apo A-I. An Apo A-I preparation is provided having at least a 12 log LRV (log reduction value) for a parvovirus; and/or at least 9 log LRV for a non-enveloped virus; and/or at least 8.5 log LRV for a lipid enveloped virus. Also provided are pharmaceutical compositions and reconstituted high density lipoprotein formulation comprising Apo A-I and methods of treating diseases disorders or conditions.Type: GrantFiled: July 31, 2020Date of Patent: August 22, 2023Assignee: CSL LimitedInventors: Gary Lee Warren, Yvonne Vucica, Christoph Kempf, Martin Stucki
-
Publication number: 20230142696Abstract: The present invention relates to reconstituted high density lipoprotein (rHDL) formulations comprising an apolipoprotein, a lipid and a lyophilization stabilizer. Said formulations have reduced renal toxicity and good long-term stability, especially in lyophilized form.Type: ApplicationFiled: September 2, 2022Publication date: May 11, 2023Applicant: CSL LimitedInventors: Yvonne Vucica, Gary Lee Warren
-
Patent number: 11464828Abstract: The present invention relates to reconstituted high density lipoprotein (rHDL) formulations comprising an apolipoprotein, a lipid and a lyophilization stabilizer. Said formulations have reduced renal toxicity and good long-term stability, especially in lyophilized form.Type: GrantFiled: March 23, 2020Date of Patent: October 11, 2022Assignee: CSL LimitedInventors: Yvonne Vucica, Gary Lee Warren
-
Patent number: 11279750Abstract: The present invention relates to processes of obtaining Apo A-1 from an Apo A-1 containing protein fraction (A), comprising suspending—the Apo A-1 containing protein fraction (A) in a buffer solution (B), removing impurities from the suspension while keeping the Apo A-1 proteins solubilized, followed by precipitating Apo A˜I from the suspension and collecting the Apo A-1 precipitate. Apo A-I obtained by such processes, reconstituted HDL obtained from such Apo A-1, and pharmaceutical compositions comprising such Apo A-I and/or reconstituted HDL also are provided.Type: GrantFiled: September 18, 2019Date of Patent: March 22, 2022Assignee: CSL LIMITEDInventors: Yvonne Vucica, Gary Lee Warren
-
Publication number: 20210147509Abstract: A method for purifying Apo A-I is provided including the steps of providing a solution comprising Apo A-I and guanidine hydrochloride and filtering the solution through a filter having a pore size in a range from 15 nm to 35 nm to thereby reduce viral contamination of the Apo A-I. An Apo A-I preparation is provided having at least a 12 log LRV (log reduction value) for a parvovirus; and/or at least 9 log LRV for a non-enveloped virus; and/or at least 8.5 log LRV for a lipid enveloped virus. Also provided are pharmaceutical compositions and reconstituted high density lipoprotein formulation comprising Apo A-I and methods of treating diseases disorders or conditions.Type: ApplicationFiled: July 31, 2020Publication date: May 20, 2021Applicant: CSL LimitedInventors: Gary Lee Warren, Yvonne Vucica, Christoph Kempf, Martin Stucki
-
Publication number: 20200397859Abstract: The present invention relates to reconstituted high density lipoprotein (rHDL) formulations comprising an apolipoprotein, a lipid and a lyophilization stabilizer. Said formulations have reduced renal toxicity and good long-term stability, especially in lyophilized form.Type: ApplicationFiled: March 23, 2020Publication date: December 24, 2020Applicant: CSL LimitedInventors: Yvonne Vucica, Gary Lee Warren
-
Patent number: 10730927Abstract: A method for purifying Apo A-I is provided including the steps of providing a solution comprising Apo A-I and guanidine hydrochloride and filtering the solution through a filter having a pore size in a range from 15 nm to 35 nm to thereby reduce viral contamination of the Apo A-I. An Apo A-I preparation is provided having at least a 12 log LRV (log reduction value) for a parvovirus; and/or at least 9 log LRV for a non-enveloped virus; and/or at least 8.5 log LRV for a lipid enveloped virus. Also provided are pharmaceutical compositions and reconstituted high density lipoprotein formulation comprising Apo A-I and methods of treating diseases disorders or conditions.Type: GrantFiled: July 20, 2018Date of Patent: August 4, 2020Assignee: CSL LIMITEDInventors: Gary Lee Warren, Yvonne Vucica, Christoph Kempf, Martin Stucki
-
Publication number: 20200223902Abstract: The present invention relates to processes of obtaining Apo A-1 from an Apo A-1 containing protein fraction (A), comprising suspending—the Apo A-1 containing protein fraction (A) in a buffer solution (B), removing impurities from the suspension while keeping the Apo A-1 proteins solubilized, followed by precipitating Apo A˜I from the suspension and collecting the Apo A-1 precipitate. Apo A-I obtained by such processes, reconstituted HDL obtained from such Apo A-1, and pharmaceutical compositions comprising such Apo A-I and/or reconstituted HDL also are provided.Type: ApplicationFiled: September 18, 2019Publication date: July 16, 2020Applicant: CSL LIMITEDInventors: Yvonne Vucica, Gary Lee Warren
-
Patent number: 10603355Abstract: The present invention relates to reconstituted high density lipoprotein (rHDL) formulations comprising an apolipoprotein, a lipid and a lyophilization stabilizer. Said formulations have reduced renal toxicity and good long-term stability, especially in lyophilized form.Type: GrantFiled: February 12, 2018Date of Patent: March 31, 2020Assignee: CSL LIMITEDInventors: Yvonne Vucica, Gary Lee Warren
-
Patent number: 10421799Abstract: The present invention relates to processes of obtaining Apo A-1 from an Apo A-1 containing protein fraction (A), comprising suspending the Apo A-1 containing protein fraction (A) in a buffer solution (B), removing impurities from the suspension while keeping the Apo A-1 proteins solubilized, followed by precipitating Apo A˜I from the suspension and collecting the Apo A-1 precipitate. Apo A-I obtained by such processes, reconstituted HDL obtained from such Apo A-1, and pharmaceutical compositions comprising such Apo A-I and/or reconstituted HDL also are provided.Type: GrantFiled: January 12, 2018Date of Patent: September 24, 2019Assignee: CSL LIMITEDInventors: Yvonne Vucica, Gary Lee Warren
-
Publication number: 20190119354Abstract: A method for purifying Apo A-I is provided including the steps of providing a solution comprising Apo A-I and guanidine hydrochloride and filtering the solution through a filter having a pore size in a range from 15 nm to 35 nm to thereby reduce viral contamination of the Apo A-I. An Apo A-I preparation is provided having at least a 12 log LRV (log reduction value) for a parvovirus; and/or at least 9 log LRV for a non-enveloped virus; and/or at least 8.5 log LRV for a lipid enveloped virus. Also provided are pharmaceutical compositions and reconstituted high density lipoprotein formulation comprising Apo A-I and methods of treating diseases disorders or conditions.Type: ApplicationFiled: July 20, 2018Publication date: April 25, 2019Applicant: CSL LimitedInventors: Gary Lee Warren, Yvonne Vucica, Christoph Kempf, Martin Stucki
-
Publication number: 20190015476Abstract: The present invention relates to reconstituted high density lipoprotein (rHDL) formulations comprising an apolipoprotein, a lipid and a lyophilization stabilizer. Said formulations have reduced renal toxicity and good long-term stability, especially in lyophilized form.Type: ApplicationFiled: February 12, 2018Publication date: January 17, 2019Applicant: CSL LimitedInventors: Yvonne Vucica, Gary Lee Warren
-
Publication number: 20180298080Abstract: The present invention relates to processes of obtaining Apo A-I from an Apo A-I containing protein fraction (A), comprising suspending the Apo A-I containing protein fraction (A) in a buffer solution (B), removing impurities from the suspension while keeping the Apo A-I proteins solubilized, followed by precipitating Apo A˜I from the suspension and collecting the Apo A-I precipitate. Apo A-I obtained by such processes, reconstituted HDL obtained from such Apo A-I, and pharmaceutical compositions comprising such Apo A-I and/or reconstituted HDL also are provided.Type: ApplicationFiled: January 12, 2018Publication date: October 18, 2018Applicant: CSL LIMITEDInventors: Yvonne Vucica, Gary Lee Warren
-
Patent number: 10087235Abstract: A method for purifying Apo A-I is provided including the steps of providing a solution comprising Apo A-I and guanidine hydrochloride and filtering the solution through a filter having a pore size in a range from 15 nrn to 35 nm to thereby reduce viral contamination of the Apo A-I. An Apo A-f preparation is provided having at least a 12 log LRV (log reduction value) for a parvovirus; and/or at least 9 log LRV for a non-enveloped virus; and/or at least 8.5 log LRV for a lipid enveloped virus. Also provided are pharmaceutical compositions and reconstituted high density lipoprotein formulation comprising Apo A-I and methods of treating diseases disorders or conditions.Type: GrantFiled: August 8, 2014Date of Patent: October 2, 2018Assignee: CSL LIMITEDInventors: Gary Lee Warren, Yvonne Vucica, Christoph Kempf, Martin Stucki
-
Patent number: 9925236Abstract: The present invention relates to reconstituted high density lipoprotein (rHDL) formulations comprising an apolipoprotein, a lipid and a lyophilization stabilizer. Said formulations have reduced renal toxicity and good long-term stability, especially in lyophilized form.Type: GrantFiled: October 31, 2013Date of Patent: March 27, 2018Assignee: CSL LIMITEDInventors: Yvonne Vucica, Gary Lee Warren
-
Patent number: 9890203Abstract: The present invention relates to processes of obtaining Apo A-1 from an Apo A-1 containing protein fraction (A), comprising suspending—the Apo A-1 containing protein fraction (A) in a buffer solution (B), removing impurities from the suspension while keeping the Apo A-1 proteins solubilized, followed by precipitating Apo A˜I from the suspension and collecting the Apo A-1 precipitate. Apo A-I obtained by such processes, reconstituted HDL obtained from such Apo A-1, and pharmaceutical compositions comprising such Apo A-I and/or reconstituted HDL also are provided.Type: GrantFiled: June 5, 2014Date of Patent: February 13, 2018Assignee: CSL LIMITEDInventors: Yvonne Vucica, Gary Lee Warren
-
Publication number: 20160176946Abstract: The present invention relates to processes of obtaining Apo A-1 from an Apo A-1 containing protein fraction (A), comprising suspending—the Apo A-1 containing protein fraction (A) in a buffer solution (B), removing impurities from the suspension while keeping the Apo A-1 proteins solubilized, followed by precipitating Apo A˜I from the suspension and collecting the Apo A-1 precipitate. Apo A-I obtained by such processes, reconstituted HDL obtained from such Apo A-1, and pharmaceutical compositions comprising such Apo A-I and/or reconstituted HDL also are provided.Type: ApplicationFiled: June 5, 2014Publication date: June 23, 2016Applicant: CSL LIMITEDInventors: Yvonne Vucica, Gary Lee Warren
-
Publication number: 20160176947Abstract: A method for purifying Apo A-l is provided including the steps of providing a solution comprising Apo A-l and guanidine hydrochloride and filtering the solution through a filter having a pore size in a range from 15 nrn to 35 nm to thereby reduce viral contamination of the Apo A-l. An Apo A-f preparation is provided having at least a 12 LRV (log reduction value) for a parvovirus; and/or at least 9 log LRV for a non-enveloped virus; and/or at least 8.5 log LRV for a lipid enveloped virus. Also provided are pharmaceutical compositions and reconstituted high density lipoprotein formulation comprising Apo A-l and methods of treating diseases disorders or conditions.Type: ApplicationFiled: August 8, 2014Publication date: June 23, 2016Applicant: CSL LimitedInventors: Gary Lee Warren, Yvonne Vucica, Christoph Kempf, Martin Stucki
-
Publication number: 20150306176Abstract: The present invention relates to reconstituted high density lipoprotein (rHDL) formulations comprising an apolipoprotein, a lipid and a lyophilization stabilizer. Said formulations have reduced renal toxicity and good long-term stability, especially in lyophilized form.Type: ApplicationFiled: October 31, 2013Publication date: October 29, 2015Applicant: CSL LimitedInventors: Yvonne Vucica, Gary Lee Warren